Home > H3D News > News

News

News

Current news articles are found here.

Dr Mathew Njoroge (H3D), in laboratory
NJOROGE TAKES NOTES FROM LAUREATES IN LINDAU
Friday, August 4, 2017 - 18:00

Postdoctoral research fellow Dr Mathew Njoroge at UCT’s Drug Discovery and Development Centre (H3D) recently returned from the 67th Lindau Nobel Laureate Meeting in Germany. The annual scientific conferences have been held in Lindau since 1951, bringing together Nobel laureates and young scientists to foster scientific exchanges between different generations and cultures.

SA MUST BUILD A SCIENCE INDUSTRY
Friday, August 4, 2017 - 18:00

There is a great need to fund talented African scientists — based in Africa — to succeed, rather than just survive, by providing world-class infrastructure. The continent is also facing a lack of scientific entrepreneurship and poorly developed scientific networks between different groups.

CALL FOR MORE INVESTMENT IN SCIENCE INFRASTRUCTURE IN AFRICA
Tuesday, July 25, 2017 - 18:00

Researcher Professor Kelly Chibale has called for a deep commitment to investing in world-class infrastructure and skills for scientists to succeed on the continent.

INVEST IN SCIENCE JOBS FOR AFRICA
Friday, July 21, 2017 - 18:00

Leading African researcher Professor Kelly Chibale has called for a deep commitment to investing in world-class infrastructure and skills to enable scientists to succeed on the continent..

Picture: THINKSTOCK
DRUGS SECTOR TIE-UPS 'CAN HELP CURE SA'
Friday, May 19, 2017 - 18:00

Production of drugs in SA instead of outsourcing to countries such as India would dent high unemployment.

Public-private partnerships in the pharmaceutical sector are vital for accelerating job creation and infrastructure development in SA, says malaria researcher Kelly Chibale.

Anopheles gambiae obtaining a blood meal from a human host. Photo Jim Gathany via Flickr.
NEW ANTIMALARIAL DRUG SHOWS PROMISE
Wednesday, April 26, 2017 - 18:00

An exciting new antimalarial drug candidate is active across the entire parasite life cycle and holds great promise as a single-dose cure.

A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new antimalarial clinical drug candidate. MMV390048 is effective against resistant strains of the malaria parasite and across the entire parasite life cycle, and it has the potential to cure and protect in a single dose.

Professor Kelly Chibale, the director of Africa's first integrated drug discovery and development center, H3D, at his laboratory at the University of Cape Town. Credit: Michael Hammond
NEW PUBLICATION HIGHLIGHTS THE ANTI-MALARIAL EFFICACY OF EXCITING NEW CLINICAL CANDIDATE
Wednesday, April 26, 2017 - 18:00

A new paper published today in the prestigious journal Science Translational Medicine describes the discovery and biological profiling of an exciting new anti-malarial clinical drug candidate, MMV390048, effective against resistant strains of the malaria parasite, and across the entire parasite lifecycle, with the potential to cure and protect in a single dose. The research was conducted by the University of Cape Town (UCT)'s Drug Discovery and Development Centre, H3D, and Medicines for Malaria Venture (MMV), in collaboration with a team of international researchers.
 

Prof Chibale in lab
BEAUTIFUL NEWS
Wednesday, April 26, 2017 - 17:00

Click here to watch the Beautiful News video  

The scientist poised to save millions from the devastation of malaria

Africa has been at the mercy of Malaria for thousands of years. Killing half a million people on the continent each year, the disease is yet to meet its equal. But this could soon change. A team of young scientists at UCT has uncovered a compound that has the potential to attack Malaria at all three stages of its cycle through the human body, with a force beyond anything in modern medicine.

 

H3D Director
EXPERT ADVISORY BOARD TO SUPPORT THE GLOBAL AMR INNOVATION FUND
Thursday, December 1, 2016 - 16:30

Professor Dame Sally Davies, the Chief Medical Officer for England and UK government adviser, has appointed an expert advisory board to support the Global Antimicrobial Resistance Innovation Fund (GAMRIF).

The 12 member board will advise how the UK can best spend an additional £50 million over the next 5 years to work with global partners to fund innovative initiatives to tackle drug resistant infections, which includes resistance to antibiotics.

AMR Innovation fund building
UCT EARNS POSITION ON INTERNATIONAL EXPERT ADVISORY BOARD TO TACKLE DRUG RESISTANT INFECTIONS
Wednesday, November 30, 2016 - 16:30

The UK government has appointed an expert advisory board to advise how it can best spend an additional 50 million British pounds over the next five years to fund innovative initiatives to tackle drug resistant infections, which include resistance to antibiotics.

Professor Kelly Chibale, founder and director of the University of Cape Town’s Drug Discovery and Development Centre (H3D) and founding director of the South African Medical Research Council/UCT drug discovery and development research unit, has been selected as a member of the advisory board.

Scientists in BSL3 lab
UCT IN GLOBAL ANTIMICROBIAL RESEARCH
Friday, September 23, 2016 - 16:30

Today 193 countries will sign a landmark declaration agreeing to combat the biggest risk to modern medicine – antimicrobial resistance ­­– at the United Nations General Assembly in New York.

 

H3D chemists in the lab
UCT’S DRUG DISCOVERY AND DEVELOPMENT CENTRE, H3D, IDENTIFIES A SECOND POTENT ANTI-MALARIAL CANDIDATE
Wednesday, July 27, 2016 - 16:30

The University of Cape Town (UCT)’s Drug Discovery and Development Centre, H3D, has identified a new potent anti-malarial development candidate with potential for both treatment and prevention of malaria

Pages